Welcome to the international HTA database

Showing [16524 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2012	NIHR Health Technology Assessment programme	Systematic review of head cooling in adults after traumatic brain injury and stroke
2012	Canadian Agency for Drugs and Technologies in Health (CADTH)	Protease inhibitor use for chronic hepatitis C infection in special populations: a review of the clinical evidence and guidelines
2012	Agency for Healthcare Research and Quality (AHRQ)	An evidence review of active surveillance in men with localized prostate cancer
2012	Agency for Healthcare Research and Quality (AHRQ)	Acute migraine treatment in emergency settings
2012	Canadian Agency for Drugs and Technologies in Health (CADTH)	Newborn screening for krabbe leukodystrophy: a review of the clinical and cost effectiveness and guidelines
2012	Agency for Healthcare Research and Quality (AHRQ)	Enabling health care decisionmaking through clinical decision support and knowledge management
2012	Agency for Healthcare Research and Quality (AHRQ)	Local hepatic therapies for metastases to the liver from unresectable colorectal cancer
2012	HTA Unit, University of Calgary	Corneal crosslinking for keratoconus and corneal crosslinking for other corneal thinning disorders
2012	NIHR Health Technology Assessment programme	Clinical effectiveness and cost-effectiveness of endobronchial and endoscopic ultrasound relative to surgical staging in potentially resectable lung cancer: results from the ASTER randomised controlled trial
2012	NIHR Health Technology Assessment programme	A systematic review of the clinical effectiveness and cost effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy
2012	Canadian Agency for Drugs and Technologies in Health (CADTH)	Smoking cessation interventions for pregnant women and mothers of infants: a review of the clinical effectiveness, safety, and guidelines
2012	Agency for Healthcare Research and Quality (AHRQ)	Evaluation and treatment of cryptorchidism
2012	HTA Unit, University of Calgary	Radiofrequency ablation for low back pain
2012	National Institute for Health and Care Excellence (NICE)	Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy. NICE technology appraisal guidance 242
2012	Canadian Agency for Drugs and Technologies in Health (CADTH)	Campus of care models for adults with disabilities and seniors: a review of clinical benefits and harms and cost-effectiveness
2012	Agency for Healthcare Research and Quality (AHRQ)	Interventions to improve patient adherence to hepatitis C treatment: comparative effectiveness
2012	National Institute for Health and Care Excellence (NICE)	Rituximab for the first-line treatment of stage III-IV follicular lymphoma. NICE technology appraisal guidance 243
2012	Canadian Agency for Drugs and Technologies in Health (CADTH)	Lipid lowering agents for stroke prevention: a review of the clinical evidence, safety and guidelines
2012	Agency for Healthcare Research and Quality (AHRQ)	Closing the quality gap: revisiting the state of the science series - Prevention of healthcare associated infections
2012	National Institute for Health and Care Excellence (NICE)	Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults. NICE technology appraisal guidance 245
2012	NIHR Health Technology Assessment programme	Adapting health promotion interventions to meet the needs of ethnic minority groups: mixed-methods evidence synthesis
2012	Canadian Agency for Drugs and Technologies in Health (CADTH)	Dabigatran for stroke prevention in atrial fibrillation: a review of the evidence on safety
2012	NIHR Health Technology Assessment programme	Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development
2012	Institute of Health Economics (IHE)	The effectiveness and safety of preschool hearing screening programs
2012	National Institute for Health and Care Excellence (NICE)	Pharmalgen for the treatment of bee and wasp venom allergy. NICE technology appraisal guidance 246
2012	HAYES, Inc.	DaTscan (123I-Ioflupane; GE Healthcare) for diagnosis of Parkinson's Disease
2012	Canadian Agency for Drugs and Technologies in Health (CADTH)	Triptans for migraine headaches: a review of clinical evidence on safety
2012	NIHR Horizon Scanning Centre (NIHR HSC)	Dacomitinib for advanced or metastatic non-small cell lung cancer – second or third line
2012	Institute of Health Economics (IHE)	The safety and effectiveness of preschool vision screening
2012	National Institute for Health and Care Excellence (NICE)	Tocilizumab for the treatment of rheumatoid arthritis. NICE technology appraisal guidance 247
2012	NIHR Health Technology Assessment programme	Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer
2012	HAYES, Inc.	Diamondback 360° Orbital Atherectomy System (Cardiovascular Systems Inc.) for percutaneous atherectomy of lower-extremity peripheral arterial disease
2012	Canadian Agency for Drugs and Technologies in Health (CADTH)	Olopatadine for the treatment of allergic conjunctivitis: a review of the clinical efficacy, safety, and cost-effectiveness
2012	NIHR Horizon Scanning Centre (NIHR HSC)	Dovitinib for metastatic renal cell carcinoma
2012	Agency for Healthcare Research and Quality (AHRQ)	Primary care relevant interventions for tobacco use prevention and cessation in children and adolescents: a systematic evidence review for the U.S. Preventive Services Task Force
2012	Institute of Health Economics (IHE)	The safety and efficacy/effectiveness of using automated testing devices for universal newborn hearing screening: an update
2012	National Institute for Health and Care Excellence (NICE)	Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 254
2012	Canadian Agency for Drugs and Technologies in Health (CADTH)	Diagnosis and treatment of pineal gland cysts: a review of the clinical effectiveness and guidelines
2012	NIHR Horizon Scanning Centre (NIHR HSC)	Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer – first line
2012	Agency for Healthcare Research and Quality (AHRQ)	Screening for HIV in pregnant women: systematic review to update the U.S. Preventive Services Task Force Recommendation.
2012	National Institute for Health and Care Excellence (NICE)	Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation. NICE technology appraisal guidance 256
2012	HAYES, Inc.	Esteem Totally Implantable Hearing System (Envoy Medical Corp.) for treatment of moderate to severe sensorineural hearing loss in adults
2012	Canadian Agency for Drugs and Technologies in Health (CADTH)	Congestive heart failure follow-up models: a review of the clinical effectiveness
2012	NIHR Horizon Scanning Centre (NIHR HSC)	Enzastaurin for diffuse large B-cell lymphoma – following complete remission
2012	Agency for Healthcare Research and Quality (AHRQ)	Screening for HIV: systematic review to update the U.S. Preventive Services Task Force Recommendation
2012	National Institute for Health and Care Excellence (NICE)	Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2. NICE technology appraisal guidance 257
2012	NIHR Health Technology Assessment programme	Management of frozen shoulder: a systematic review and cost-effectiveness analysis
2012	Canadian Agency for Drugs and Technologies in Health (CADTH)	Double gloves for prevention of transmission of blood borne pathogens to patients: a review of the clinical evidence
2012	NIHR Horizon Scanning Centre (NIHR HSC)	Everolimus (Afinitor) for advanced, unresectable or metastatic neuroendocrine tumours
2012	Agency for Healthcare Research and Quality (AHRQ)	Challenges in synthesizing and interpreting the evidence from a systematic review of multifactorial interventions to prevent functional decline in older adults
2012	National Institute for Health and Care Excellence (NICE)	Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer. NICE technology appraisal guidance 258
2012	NIHR Health Technology Assessment programme	The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders
2012	NIHR Health Technology Assessment programme	Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses
2012	Canadian Agency for Drugs and Technologies in Health (CADTH)	Immune response to hepatitis B vaccination: a review of the clinical evidence
2012	NIHR Horizon Scanning Centre (NIHR HSC)	Nanoliposomal irinotecan for metastatic pancreatic cancer in patients who have progressed on prior gemcitabine-based therapy
2012	Agency for Healthcare Research and Quality (AHRQ)	Menopausal hormone therapy for the primary prevention of chronic conditions: systematic review to update the 2002 and 2005 U.S. Preventive Services Task Force Recommendations.
2012	National Institute for Health and Care Excellence (NICE)	Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen. NICE technology appraisal guidance 259
2012	HAYES, Inc.	Genesis II total knee system with oxinium femoral implants (Smith and Nephew Inc.) for total knee arthroplasty
2012	Canadian Agency for Drugs and Technologies in Health (CADTH)	Medication reconciliation at discharge: a review of the clinical evidence and guidelines
2012	NIHR Horizon Scanning Centre (NIHR HSC)	Ofatumumab (Arzerra) for maintenance treatment in relapsed chronic lymphocytic leukaemia (CLL) patients responding to induction therapy
2012	Agency for Healthcare Research and Quality (AHRQ)	Screening women for intimate partner violence and elderly and vulnerable adults for abuse: systematic review to update the 2004 U.S. Preventive Services Task Force Recommendation.
2012	National Institute for Health and Care Excellence (NICE)	Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. NICE technology appraisal guidance 260
2012	NIHR Health Technology Assessment programme	Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying antirheumatic drugs
2012	HAYES, Inc.	Glucarpidase (Voraxaze; BTG International Ltd.) for treatment of high-dose methotrexate-induced nephrotoxicity
2012	Canadian Agency for Drugs and Technologies in Health (CADTH)	Day programming for post-traumatic stress disorder: a review of the clinical effectiveness, cost-effectiveness and guidelines
2012	NIHR Horizon Scanning Centre (NIHR HSC)	Pomalidomide for multiple myeloma – third line
2012	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Day surgery: a systematic overview]
2012	National Institute for Health and Care Excellence (NICE)	Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. NICE technology appraisal guidance 261
2012	National Institute for Health and Care Excellence (NICE)	Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M. NICE diagnostics guidance 6
2012	Canadian Agency for Drugs and Technologies in Health (CADTH)	AmniSure versus fern testing to assess the rupture of fetal membranes in pregnant women: a review of the comparative accuracy, cost-effectiveness, and guidelines
2012	NIHR Horizon Scanning Centre (NIHR HSC)	Velimogene aliplasmid (Allovectin) for advanced or metastatic malignant melanoma
2012	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Trametinib for advanced or metastatic BRAF V600E mutation-positive melanoma
2012	Agency for Healthcare Research and Quality (AHRQ)	Treatment for restless legs syndrome
2012	National Institute for Health and Care Excellence (NICE)	Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer. NICE technology appraisal guidance 263
2012	National Institute for Health and Care Excellence (NICE)	SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver. NICE diagnostics guidance 5
2012	Canadian Agency for Drugs and Technologies in Health (CADTH)	Procedure site bleeding complications following percutaneous coronary interventions or angioplasty: a review of clinical evidence and guidelines
2012	NIHR Horizon Scanning Centre (NIHR HSC)	Vinflunine (Javlor) monotherapy for advanced breast cancer
2012	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Avastin® for age-related macular degeneration]
2012	Agency for Healthcare Research and Quality (AHRQ)	Strategies to reduce cesarean birth in low-risk women
2012	National Institute for Health and Care Excellence (NICE)	Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours. NICE technology appraisal guidance 265
2012	National Institute for Health and Care Excellence (NICE)	Laparoscopic gastric plication for the treatment of severe obesity. NICE interventional procedures guidance 432
2012	Canadian Agency for Drugs and Technologies in Health (CADTH)	Codeine and acetaminophen for pain relief: a review of the clinical efficacy and safety
2012	NIHR Horizon Scanning Centre (NIHR HSC)	Cangrelor to reduce platelet aggregation and thrombosis in patients undergoing percutaneous coronary intervention
2012	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	IFEDH - Innovative Framework for Evidence Based Decision Making in Health Care: Standards on how to parameterise models via published literature: Input of the LBI-HTA (WP 4.2)
2012	Agency for Healthcare Research and Quality (AHRQ)	Comparison of characteristics of nursing homes and other residential long-term care settings for people with dementia
2012	National Institute for Health and Care Excellence (NICE)	Mannitol dry powder for inhalation for treating cystic fibrosis. NICE technology appraisal guidance 266
2012	National Institute for Health and Care Excellence (NICE)	Percutaneous laser atherectomy as an adjunct to balloon angioplasty (with or without stenting) for peripheral arterial disease. NICE interventional procedures guidance 433
2012	Canadian Agency for Drugs and Technologies in Health (CADTH)	Point-of-care testing: a review of systematic reviews on testing accuracy and cost-effectiveness
2012	NIHR Horizon Scanning Centre (NIHR HSC)	SAR236553/REGN727 for the reduction of elevated total cholesterol and low density lipoprotein cholesterol
2012	Agency for Healthcare Research and Quality (AHRQ)	Procalcitonin-guided antibiotic therapy
2012	National Institute for Health and Care Excellence (NICE)	Ivabradine for treating chronic heart failure. NICE technology appraisal guidance 267
2012	National Institute for Health and Care Excellence (NICE)	Radiofrequency cold ablation for respiratory papillomatosis. NICE interventional procedures guidance 434
2012	HAYES, Inc.	Hysteroscopic morcellation (Truclear Morcellator System; Smith & Nephew Inc.) for treatment of uterine submucosal fibroids and endometrial polyps
2012	Canadian Agency for Drugs and Technologies in Health (CADTH)	Opioid management practices for the prevention of drug diversion and misuse: a review of the clinical evidence and guidelines
2012	NIHR Horizon Scanning Centre (NIHR HSC)	Spartan RX™ point-of-care DNA test for identifying the CYP2C19*2 mutation
2012	Agency for Healthcare Research and Quality (AHRQ)	Physical therapy interventions for knee pain secondary to osteoarthritis
2012	National Institute for Health and Care Excellence (NICE)	Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma. NICE technology appraisal guidance 268
2012	National Institute for Health and Care Excellence (NICE)	Endovascular stent insertion for intracranial atherosclerotic disease. NICE interventional procedures guidance 429
2012	Agency for Healthcare Research and Quality (AHRQ)	Reliability testing of the AHRQ EPC approach to grading the strength of evidence in comparative effectiveness reviews
2012	Canadian Agency for Drugs and Technologies in Health (CADTH)	Abuse and misuse potential of pregabalin: a review of the clinical evidence